AUTHORS
Yanyan Bai, Yaping G Zhang2, Can Wang3, Andrew G Mack4, Xiaoping Du, MD, PhD5
AFFILIATIONS
1 Unviversity of Illinois Chicago, Chicago, United States
2 Unviversity of Illinois Chicago, Chicago, United States
3 Unviversity of Illinois Chicago, Chicago, United States
4 Unviversity of Illinois Chicago, Chicago, United States
5 Unviversity of Illinois Chicago, Chicago, United States
ABSTRACT
Background: Anti-platelet drugs such as clopidogrel and aspirin are necessary and routinely used in treatment of heart attack together with percutaneous coronary intervention (PCI), bypass surgery and thrombolytic therapy. However, Anti-platelet drugs are not effective in treating myocardial ischemia & Reperfusion injury (MIRI), in which initial ischemic myocardial injury is followed by oxidative and inflammatory assault on injured tissues upon reperfusion and subsequent thrombo-inflammation. Also, clinical trials of several anti-inflammatory drugs for treating MIRI also failed. The reasons for this ineffectiveness of anti-platelet and anti-inflammatory drugs are unclear. We have recently reported a new peptide-based anti-platelet drug with anti-inflammatory properties, M3mP6 high-loading peptide nanoparticles (HLPN), which potently inhibits arterial thrombosis but, unlike current anti-platelet drugs, does not exacerbate hemorrhage and vascular leakage. Here we have directly compared therapeutic effect of M3mP6 HLPN with the current anti-platelet drugs, clopidogrel and aspirin, and tested the additive effects of M3mP6 with clopidogrel and aspirin in a mouse model myocardial ischemia-reperfusion injury.
Methods: The left anterior descending (LAD) coronary artery ligation & reperfusion were preceded in 8-12 weeks old C57 mice. Mice were treated with M3mP6 HLPN or scrambled peptide HLPN starting 50 min after the ligation and 10 min before reperfusion (5 µmol/kg bolus iv injection followed by continuously infusion at rate of 2.5 µmol/kg/h for 24 hours. Clopidogrel (4 mg/kg) or aspirin (4.3 mg/kg) were administered by i.p. injection immediately after the coronary ligation. Starting 24 hours after the procedure, same dose of clopidogrel or aspirin were given orally q.d. for 6 days. Mice were examined by echocardiography 24 hrs and 7 days after the procedure and analyzed for left ventricular ejection fraction (LVEF). 7 days survival was evaluated. The heart samples were collected 24 hrs and 7 days, and analyzed using H&E staining and anti-hemoglobin antibodies staining.
Results: Following MIRI, mice treated with saline showed impaired cardiac function as indicated by the decreased LVEF at 24 hrs. Clopidogrel treatment showed a trend of partial beneficial effect on LVEF, but the difference was not significant. In contrast, M3mP6 showed significant effect in improving LVEF not only compared to saline control but also clopidogrel treatment. However, when used together with clopidogrel, the effect of M3mP6 in improving LVEF was diminished to the level of clopidogrel, suggesting a dominant effect of clopidogrel. Also, 7 days survival analysis shows that M3mP6 significantly improves survival rate as compared with saline control or clopidogrel, whereas clopidogrel alone showed no significant improvement as compared with saline. When used together, the efficacy of M3mP6 in improving survival was diminished by the clopidogrel, again suggesting a dominant negative effect of clopidogrel in counteracting the beneficial effect of M3mP6. Similar results were shown in comparison of M3mP6 with aspirin as well as P2Y12 inhibitor cangrelor (i.v. bolus 30 mg/kg was given 10 minutes before reperfusion, followed by continuous infusion at a rate of 4 μg/kg/min for 24 hrs). Histological studies show that saline control and clopidogrel treatment are associated with significantly increased hemorrhage in the cardiac tissue, in contrast to lack of hemorrhage in M3mP6-treated heart. However, when mice were treated with clopidogrel and M3mP6 together, cardiac hemorrhage is similar to clopidogrel treatment alone suggesting this adverse effect of clopidogrel is also dominant.
Conclusion: Cardiac hemorrhage (or vascular leakage) during MIRI is dominantly associated with the poor outcome of MIRI and efficacy of anti-platelet drugs in treating MIRI is associated with the absence of adverse effect on hemorrhage/vascular leakage.
DISCLOSURES
Yanyan Bai: No relevant conflicts of interest to declare.